Athenex
Athenex's Overview
Athenex, Inc. was a global biopharmaceutical company primarily focused on the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company's strategy involved an integrated approach, from drug discovery and preclinical research to clinical development and manufacturing. Athenex's key research areas included its Orascovery platform, aimed at enabling oral administration of chemotherapy agents, and cell therapy initiatives. In May 2023, Athenex filed for Chapter 11 bankruptcy protection to facilitate a wind-down of its operations and the sale of its assets. Key assets, including its oncology product Klisyri, its Dunkirk manufacturing facility, and its China-based API business, were subsequently sold throughout 2023 as part of this restructuring process.
Where is Athenex's Headquarters?
HQ Function
Served as the corporate headquarters, housing executive leadership, administrative functions, and oversight for global research, development, and clinical operations prior to its restructuring.
Notable Features:
Located in the Conventus Building, a modern facility designed to foster collaboration within the Buffalo Niagara Medical Campus, which includes Roswell Park Comprehensive Cancer Center.
Work Culture:
Historically, Athenex aimed to cultivate an innovative and collaborative work environment focused on advancing cancer treatments. Post-restructuring, activities are centered on winding down operations and managing remaining obligations.
HQ Significance:
The Buffalo headquarters was central to Athenex's U.S. operations and symbolized its commitment to innovation within a prominent medical and research hub.
Values Reflected in HQ: The headquarters' location historically reflected Athenex's values of innovation, scientific collaboration, and integration within the broader medical research community.
Location:
Prior to its Chapter 11 filing and subsequent asset sales in 2023, Athenex operated globally. Its functions included research and development primarily in the United States; API and drug product manufacturing in the U.S. (Dunkirk, NY - sold) and China (Chongqing - sold); clinical trial operations across North America, Europe, and Asia-Pacific; and commercial activities for its approved products in the U.S. and Europe (European assets sold). Hong Kong served as an important administrative and strategic hub for its Asian operations.
Street Address:
1001 Main Street, Suite 600
City:
Buffalo
State/Province:
New York
Country:
USA
Athenex's Global Presence
Dunkirk, New York, USA
Address: 340 Point Drive North, Dunkirk, NY 14048 (approximate)
Designed to be a cornerstone of Athenex's North American manufacturing capabilities and supply chain for proprietary and generic drugs.
Chongqing, China
Address: [Address part of Athenex Pharmaceutical (Chongqing) Co., Ltd., specific public address not listed]
Crucial for Athenex's global supply chain, focusing on API production and research, leveraging manufacturing expertise in China.
Manchester, United Kingdom (European Hub)
Address: [Operations managed via Athenex Europe Ltd. and other regional entities]
Managed Athenex's product approvals, market access, and commercial activities within the European Union and the UK.
Hong Kong SAR
Address: [Specific public address not listed, served as regional administrative hub]
To facilitate and manage Athenex's strategic initiatives and collaborations within the Asia-Pacific region.
Buying Intent Signals for Athenex
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Athenex
As of April 2025, Athenex' leadership includes:
Investors of Athenex
Athenex has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
The period from May 2023 to May 2024 was marked by significant leadership changes at Athenex, primarily driven by the company's Chapter 11 bankruptcy filing in May 2023 and subsequent restructuring. This included key departures and appointments to manage the wind-down and asset sale process.
Departures
New Appointments:
Technology (Tech Stack) used by Athenex
Discover the tools Athenex uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Athenex Email Formats and Examples
Athenex likely used standard corporate email address formats. Common patterns include combining the first initial and last name, or the full first and last name separated by a period, followed by '@athenex.com'. Given the company's restructuring, deliverability to historical addresses is highly uncertain.
[first_initial][last]@athenex.com (e.g., jdoe@athenex.com) or [first].[last]@athenex.com (e.g., jane.doe@athenex.com)
Format
jdoe@athenex.com
Example
60%
Success rate
News and media
Athenex Investor Relations • May 15, 2023
Athenex Files Voluntary Chapter 11 Petitions to Pursue Sale of Assets and Address Debt
Athenex announced its filing for Chapter 11 bankruptcy to facilitate an orderly sale of its assets and wind-down of operations. The company initiated processes to sell its main business units....more
Almirall Press Release / PR Newswire • July 12, 2023
Almirall completes acquisition of Athenex's US and European oncology business
Almirall S.A. finalized its acquisition of Athenex's U.S. and European dermatology business assets, most notably including the actinic keratosis treatment Klisyri (tirbanibulin)....more
ImmunityBio Press Release / Business Wire • November 2, 2023
ImmunityBio Acquires Athenex’s Manufacturing Facility in Dunkirk, New York, to Expand Vaccine and Cell Therapy Manufacturing Capacity
ImmunityBio announced the completion of its acquisition of Athenex's large-scale pharmaceutical manufacturing facility in Dunkirk, NY, to enhance its production capabilities for vaccines and cell therapies....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Athenex, are just a search away.